Novartis AG
Market cap $294.6B
$155.01
NVS
$155.01
-0.72% today
Buy with €1M virtual cash · No real money
Novartis AG (NVS) is a publicly traded company listed on the XNYS. As of July 27, 2026, Invest's signal rates NVS a Buy, with the stock up 31% over the past year. You can practice trading NVS risk-free with €1,000,000 in virtual cash.
Key stats
As of July 27, 2026
Market Cap
$294.6B
Volume
1.8M
52-wk High
$170.46
52-wk Low
$112.34
Day High
$156.38
Day Low
$154.44
Performance
1M
+1.2%
6M
+6.9%
1Y
+31.4%
Invest signal · NVS
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
NVS overview
AI overviewLatest NVS news
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
The Motley Fool · 4d ago
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035
GlobeNewswire Inc. · 4d ago
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies
GlobeNewswire Inc. · 6d ago
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
GlobeNewswire Inc. · Jul 16
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
GlobeNewswire Inc. · Jul 15
About Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises.
The company sells its products globally, with the United States constituting close to one-third of total revenue.
Employees
75,267
30-Day Win Rate · NVS
11 days
12 days
Last 23 sessions
How to practice trading NVS
- 1
Use the NVS buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top NVS traders on Invest
Full leaderboardFrequently asked questions
Is NVS a good stock to buy right now?
As of July 27, 2026, Invest's signal rates NVS a Buy, based on its price trend, valuation, and fundamentals, with the stock up 31% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading NVS risk-free first.
What is Novartis AG's (NVS) market cap?
Novartis AG has a market capitalization of approximately $294.6B.
How has NVS stock performed?
NVS is up 31% over the past year and up 7% over six months. Its 52-week range runs roughly from $112.34 to $170.46. Past performance doesn't predict future results.
How can I practice trading NVS for free?
On Invest you get €1,000,000 in virtual cash and can buy NVS at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare NVS with peers